These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cancer mortality and incidence among a cohort of benzidine and dichlorobenzidine dye manufacturing workers.
    Author: Rosenman KD, Reilly MJ.
    Journal: Am J Ind Med; 2004 Nov; 46(5):505-12. PubMed ID: 15490466.
    Abstract:
    BACKGROUND: Benzidine is classified as a definite human carcinogen and dichlorobenzidine as a probable human carcinogen. METHODS: A cohort study of 538 workers potentially exposed to benzidine and/or dichlorobenzidine from a single chemical manufacturing facility was conducted. Social Security records were used to identify all employees who worked at the facility from 1960 to 1977. Vital status was determined through 2001 and cancer incidence through 2002. RESULTS: A total of 22 bladder cancer cases were identified. For three individuals, bladder cancer was the underlying cause of death. Increased standardized mortality ratios (SMRs) were found for all cancer 1.54 (95% CI 1.04-2.19), bladder cancer 8.34 (95% CI 1.72-24.78), and lymphohematopoietic cancer 2.84 (95% CI 1.04-6.18). The standardized incidence ratio (SIR) for bladder cancer was 6.85 (95% CI 4.30-10.4). Only one case of bladder cancer was identified among the workers who were exposed to dichlorobenzidine only. However, an increased risk for lymphohematopoietic cancer was found among these dichlorobenzidine only workers (SMR 6.62 (95% CI 1.37-19.36)). CONCLUSIONS: This study confirms the high risk of bladder cancer among benzidine exposed workers even years after exposure has ceased, and raises suggestive evidence of increased risk to lymphohematopoietic cancer from exposure to benzidine or dichlorobenzidine.
    [Abstract] [Full Text] [Related] [New Search]